Proof-of-concept for MUC1 as an effective CAR-T target is evident in breast cancer, where TAB004 (mAb targeting glycosylated MUC1), engineered into CAR-T format, has shown target-specific cytotoxicity, cytokine secretion and reduced tumour burden in a xenograft model [89]. Here, MUC1 is linked to breast cancer.